Near Vergence Training for Distance Control in Intermittent Exotropia
Evaluating Near Vergence Training for Distance Control in Basic and Divergence Excess Intermittent Exotropia
Intermittent Exotropia (IXT) is a common type of eye misalignment where one eye periodically turns outward, and control is typically much worse when looking at objects far away than close up. However, most currently available training programme are focused on near-viewing tasks. The goal of this clinical trial is to investigate if a new, structured, home-based near eye training program works to improve distance eye alignment control in children and young adults with IXT.
The main questions the study aims to answer are:
- Does a 12-week near eye training program improve a participant's ability to control their eye alignment when looking at a distance?
- Does using a special reading glasses during near training help to control distance eye alignment better than doing the training without the reading glasses?
- Do the benefits of this eye training last after the training has stopped?
This is a two- phase, single- masked (examiner masked), randomized clinical trial with crossover design. The entire study duration is about 24 weeks. A total sample size of 42 participants, aged 6 to 25 years with diagnosed Basic (distance deviation is within 10 prism diopters of the near deviation) or Divergence excess (distance deviation is at least 10 prism diopters greater than the near deviation) IXT, will be recruited.
In Phase I (Weeks 0 to 12), participants will be randomly allocated into one of three groups, with 14 individuals in each group:
- Group 1 does eye training while wearing special plus-power reading glasses that remove the need to focus up close, mimicking how the eyes look at a distance.
- Group 2 does the exact same eye training but wears regular distance glasses without the special reading addition.
- Group 3 serves as a control group that does not do training during the first 12 weeks, but will receive the training in the second phase.
In Phase II (Weeks 13 to 24), which is a crossover phase, groups 1 and 2 will stop training to see if the visual improvements last, while group 3 will be re-randomized into two subgroups (group 3A, with special plus-power reading glasses, and group 3B with regular glasses with distance correction) that will undertake daily eye training for 12 weeks to ensure ethical treatment access. All participants will have a final eye exam at 24 weeks.
During home training, participants will:
- Wear standard glasses provided by the study.
- Practice daily, home-based eye exercises for 12 weeks using a standardized software program on a computer or tablet.
- Complete 3 training sessions every day, lasting 7 minutes per session.
- Wear red-blue 3D glasses during training and press arrow keys or swipe the screen to play a visual game that dynamically changes in difficulty.
Preliminary test and binocular vision assessment with fixed and uniform sequence will be performed at baseline visit, 6th week interim visit, 12th and 24th week evaluation. All eye examinations will be carried out in The Optometry Centre (A034), the School of Optometry, The Hong Kong Polytechnic University.
The following data will be statistically analyzed. The primary outcome data is distance Office Control Score (OCS) at 12-week visit. Secondary outcomes data include change in deviation angle, near and distance stereopsis and patient- / parent- reported health-related quality-of-life questions at 12-week.
調査の概要
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Horace Ho-yin Wong, MClinOptom, BSc (Hons) Optom
- 電話番号:852-63384048
- メール:horace.wong@polyu.edu.hk
研究連絡先のバックアップ
- 名前:Tsz Wing Leung, PhD
- 電話番号:852- 27664268
- メール:jeffrey.TW.leung@polyu.edu.hk
研究場所
-
-
-
Hong Kong、香港
- 募集
- The Optometry Clinic, The Hong Kong Polytechnic University
-
コンタクト:
- Horace Ho-yin Wong, MClinOptom, BSc (Hons) Optom
- 電話番号:852-63384048
- メール:horace.wong@polyu.edu.hk
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria
-
Age and Diagnosis: Participants must be aged 6 to ≤ 25 years at the time of screening, with a confirmed clinical diagnosis of either Basic or Divergence Excess (DE) Intermittent Exotropia (IXT).
-
Ocular Alignment Magnitude: Distance exodeviation measuring between 10 and 40 prism diopters (pd) inclusive, determined by the prism and alternate cover test (PACT).
-
Distance-Near Disparity Limits: Near exodeviation must not exceed the distance exodeviation by more than 10 pd (to exclude Convergence Insufficiency type exotropia).
-
Baseline Distance Control: A baseline distance IXT Office Control Score (OCS) between Grade 2 and Grade 4 inclusive, based on the mean of 3 standardized assessments.
-
Baseline Near Control: A baseline near IXT control score less than or equal to the distance IXT control score, based on the mean of 3 standardized assessments.
-
Visual Acuity: Best-corrected visual acuity (BCVA) of Logarithm of the Minimum Angle of Resolution (logMAR) 0.1 or better in each eye at both distance and near fixation.
-
Sensory Status: Measurable near stereoacuity of 400 arc seconds or better on the Preschool Randot stereoacuity test.
-
Refractive Correction Stability: Compliance with wearing a stable, appropriate spectacle correction for ≥ 4 months prior to formal baseline assessment if the participant meets any of the following refractive thresholds:
- Myopia < -0.50D spherical equivalent (SE) in either eye.
- Hyperopia > +2.50D SE in either eye.
- Anisometropia > 1.00 SE.
- Astigmatism > 1.50D cylinder in either eye.
-
Treatment History: No history of prior non-surgical interventions for IXT, including patching, vision therapy/orthoptics, or overminus lens therapy (≥ 0.50 D).
-
Surgical History: No prior history of strabismus surgery, extraocular muscle botulinum toxin injections, intraocular surgery, or refractive surgery.
-
Trial Commitment: No planned strabismus surgery or conflicting ocular therapies during the 24-week study period.
Exclusion Criteria
- Amblyopia and Co-morbid Strabismus: Presence of amblyopia, nystagmus, restrictive strabismus, or paretic strabismus.
- Vertical Misalignment: Presence of an associated vertical ocular deviation > 5 pd.
- Significant Pathologies: Co-existing significant ocular disease or neurological disorders (e.g., cerebral palsy) that could confound oculomotor or sensory evaluations.
- Confounding Medications: Regular use of systemic or topical ocular medications known to alter accommodative or vergence function within the 3 months prior to screening (including, but not limited to, atropine, pirenzepine, or systemic anti-epileptic agents).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Active training group with reading glasses
Receiving training in Phase I (Weeks 0 to 12), stop training in Phase II (Weeks 13 to 24) to study the effect persistence |
Standardized home-based near vergence training platform with data visualization tools and communication platforms |
|
アクティブコンパレータ:Active training group without reading glasses
Receiving training in Phase I (Weeks 0 to 12), stop training in Phase II (Weeks 13 to 24) to study the effect persistence |
Standardized home-based near vergence training platform with data visualization tools and communication platforms |
|
介入なし:Control group
No training will be received in Phase I (Weeks 0 to 12); Will receive training in Phase II of the study (Weeks 13 to 24) to ensure ethical treatment access |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change of Distance Office Control Score
時間枠:Baseline, 6-week, 12-week and 24-week
|
Objective and quantitative office control scale, based on the frequency of deviation and the recovery speed followed by occlusion. Ranged from 0 to 5, with score 0 represents the best control (phoria with excellent control), and score 5 represents the worst control (constant exotropia during the 30-second observation) |
Baseline, 6-week, 12-week and 24-week
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change of exodeviation magnitude angle
時間枠:Baseline, 6-week, 12-week and 24-week
|
measured by Prism and Alternate Cover Test, ranged from 1 to 50 prism diopter. The higher the value, the worse is the magnitude angle of the exodeviation |
Baseline, 6-week, 12-week and 24-week
|
|
Change of Distance stereoacuity
時間枠:Baseline, 6-week, 12-week and 24-week
|
measured by Distance Randot® stereotest, ranged from 400 seconds of arc (the worst measurable stereoacuity) to 60 seconds of arc (the best measurable stereoacuity ) |
Baseline, 6-week, 12-week and 24-week
|
|
Change of Near stereoacuity
時間枠:Baseline, 6-week, 12-week and 24-week
|
measured by Preschool Randot® stereoacuity test, ranged from 800 seconds of arc (the worst measurable stereoacuity) to 40 seconds of arc (the best measurable stereoacuity ) |
Baseline, 6-week, 12-week and 24-week
|
|
Change of Quality of Life (QoL) measures - Chinese Intermittent Exotropia Questionnaire (CIXTQ) for children aged 5 to 17 and parents of children aged 2 to 17
時間枠:Baseline, 12-week and 24-week
|
Part a: Child CIXTQ - 12 items completed by children, simplified 3-point scale (0, 50 and 100); Part b: Proxy CIXTQ - 12 items completed by parents to evaluate their child's health-related quality-of-life (HRQoL) from a parental perspective, 5-point Likert-type (0, 25, 50, 75, and 100); Part c: Parent CIXTQ - 17 items to measure the parent's own HRQoL, 5-point Likert-type (0, 25, 50, 75 and 100). The higher the score, the better the outcome (QoL). |
Baseline, 12-week and 24-week
|
|
Change of Quality of Life (QoL) measures - The Chinese Adult Strabismus Quality of Life Questionnaire (CAS-20) for adult participants aged 18 or above
時間枠:Baseline, 12-week and 24-week
|
20 items to assess psychosocial impact and visual function, 5-point Likert-type (0, 25, 50, 75 and 100). Higher scores indicating better perceived QoL. |
Baseline, 12-week and 24-week
|
協力者と研究者
出版物と役立つリンク
一般刊行物
- Mohney BG, Holmes JM. An office-based scale for assessing control in intermittent exotropia. Strabismus. 2006 Sep;14(3):147-50. doi: 10.1080/09273970600894716.
- Ma MM, Kang Y, Scheiman M, Chen Q, Ye X, Pan L, Deng J, Su G, Zhang G, Chen X. Office-based vergence and anti-suppression therapy for the treatment of small-to-moderate angle intermittent exotropia: A randomised clinical trial. Ophthalmic Physiol Opt. 2024 Mar;44(2):356-377. doi: 10.1111/opo.13264. Epub 2023 Dec 26.
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
その他の研究ID番号
- HSEARS20251213004
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。